mass spectrometry is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
Reversed-phase high-performance liquid chromatography is the routine method for purity assessment. Peptides absorb near 214 nm because of the peptide bond, and a gradient of acetonitrile in water separates the intact peptide from deletion sequences, oxidised products, and earlier-eluting fragments at neutral pH. Electrospray ionisation mass spectrometry provides an orthogonal check: the measured mass must agree with the theoretical value. Amino acid analysis and peptide mapping confirm structure but are used less often. Reference standards remain scarce because the peptide is not described in any pharmacopoeia.
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms add to total mass |
| Molecular mass | About 1024 daltons | Calculated for the free base |
| Structural class | Cyclic heptapeptide | Contains D-phenylalanine and norleucine |
| Parent hormone | Alpha-melanocyte-stimulating hormone | Endogenous tridecapeptide of 13 residues |
| Receptor profile | Non-selective melanocortin agonist | Interacts with MC1R, MC3R, MC4R and MC5R |
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
=== Similar species === Several species may be confused with A. campestris. The most dangerous confusion may be with the deadly Amanita virosa (a 'destroying angel') or the deadly Amanita hygroscopica (pink-gilled destroying angel). Amanita species may be distinguished from Agaricus by a volva at the base, remnants of a universal veil. Such a veil may also be seen surrounding adjacent smaller button mushrooms, if present. It's recommended to look for smaller sibling buttons nearby, and slice one of them lengthwise to examine their anatomy. They may also be distinguished by a white or off-white spore print while mushrooms in the family Agaricacea are dark brown. In the United States, the poisonous Agaricus californicus and A. hondensis may be similar. White Clitocybe species that also grow in grassy places may be toxic. A less serious, but more common, confusion is with Agaricus xanthodermus (the yellow stainer), which causes gastrointestinal problems in many people. A. arvensis (the horse mushroom) is very similar and is an excellent edible. It is nearly identical (except microscopically) to the edible species Agaricus andrewii and A. solidipes.
== Carcinoma in situ (230–234) == 230 Carcinoma in situ of digestive organs 231 Carcinoma in situ of respiratory system 232 Carcinoma in situ of skin 233 Carcinoma in situ of breast and genitourinary system 234 Carcinoma in situ of other and unspecified sites
Hayes, Sean (2022), "Burning Fat & Calories Post-Workout via the Afterburn Effect/EPOC." The Pliagility Blog. Lecheminant, J.; Jacobsen, D.; Bailey, B.; Mayo, M.; Hill, J.; Smith, B.; Donnelly, J. (2008). "Effects of Long-Term Aerobic Exercise on EPOC". International Journal of Sports Medicine. 29 (1): 53–8. doi:10.1055/s-2007-965111. PMID 17879880. Matsuo, Tomoaki; Ohkawara, Kazunori; Seino, Satoshi; Shimojo, Nobutake; Yamada, Shin; Ohshima, Hiroshi; Tanaka, Kiyoji; Mukai, Chiaki (2012). "Cardiorespiratory fitness level correlates inversely with excess post-exercise oxygen consumption after aerobic-type interval training". BMC Research Notes. 5: 646. doi:10.1186/1756-0500-5-646. PMC 3527216. PMID 23171610. Zeng, Ling-Qing; Zhang, Yao-Guang; Cao, Zhen-Dong; Fu, Shi-Jian (2010). "Effect of temperature on excess post-exercise oxygen consumption in juvenile southern catfish (Silurus meridionalis Chen) following exhaustive exercise". Fish Physiology and Biochemistry. 36 (4): 1243–52. doi:10.1007/s10695-010-9404-9. PMID 20499273. S2CID 24695117. Scott, Christopherb; Littlefield, Nathanaeld; Chason, Jeffreyd; Bunker, Michaelp; Asselin, Elizabethm (2006). "Differences in oxygen uptake but equivalent energy expenditure between a brief bout of cycling and running". Nutrition & Metabolism. 3: 1. doi:10.1186/1743-7075-3-1. PMC 1334197. PMID 16390548. Scott, Christopher (2005). "Misconceptions about Aerobic and Anaerobic Energy Expenditure". Journal of the International Society of Sports Nutrition. 2 (2): 32–7. doi:10.1186/1550-2783-2-2-32. PMC 2129144. PMID 18500953.
Sources: en.wikipedia.org
These new RNA transcripts are then used to repeat the selection cycle many times, thus eventually producing a homogeneous pool of RNA aptamers capable of highly specific, high-affinity target binding.
== Political composition == It was possible for the ILEA to have a majority of Labour members when the GLC had a majority of Conservative members, and this happened from 1970 to 1973 and 1977 to 1981. In addition, most of the important decisions taken by the ILEA were taken by its Education Committee, on which every member sat. The Education Committee could also co-opt members with experience of education, some of them representing the teaching unions. The initial composition of the ILEA in 1964 was 43 Labour members to 9 Conservatives, with one Independent. After the 1967 election the Conservatives won a majority, and Christopher Chataway became Leader. However, Labour won control in 1970 and Ashley Bramall began his long leadership. His term saw the ILEA go over to comprehensive education, and the abolition of school corporal punishment. He retained power despite the Conservative election victory in the 1977 GLC elections. When the Left, under Ken Livingstone, won control of the GLC after the 1981 elections, Bramall lost his position in an internal Labour Party vote, being replaced by Bryn Davies. Livingstone later expressed regret for this decision and expressed his admiration for Bramall's leadership abilities. The remaining years of the ILEA saw a succession of left-wing leaderships, none of which lasted long or established a strong reputation. Frances Morrell, formerly an assistant to Tony Benn, led a feminist ILEA from 1983 to 1987 which threatened to defy its rate-capping in November 1984, before Neil Fletcher took over.
December 13: Constitution of 22 Frimaire Year VIII (establishing the Consulate) grants citizenship only to men over 21, born and residing in France, and registered in their commune's civic registry, effectively excluding women. 1800
Sources: en.wikipedia.org
== Founding fathers of the United States == John Jay (King's 1764), president of the Continental Congress; first chief justice of the United States; author of five of The Federalist papers; first secretary of foreign affairs under the Articles of Confederation; architect of Jay Treaty with Great Britain Robert Livingston (King's 1764), a writer of the Declaration of Independence as part of the Committee of Five; first U.S. secretary of foreign affairs; negotiator of the Louisiana Purchase Egbert Benson (King's 1765), delegate to the Continental Congress, U.S. representative, first New York State attorney general, chief justice of the New York Supreme Court Gouverneur Morris (King's 1768), represented Pennsylvania in the Continental Congress; authored much of the United States Constitution; U.S. ambassador to France; United States senator from New York Alexander Hamilton* (King's 1776), American Revolutionary War officer, aide-de-camp to George Washington; most prolific writer of The Federalist Papers; first United States secretary of the treasury, portrayed on the ten-dollar bill; founder of the Bank of New York
Autolytic debridement: The most conservative type of debridement whereby the body's own natural defenses break down necrotic tissue via phagocytes and proteolytic enzymes. This method requires a moist environment and intact immune system. Mechanical debridement: Achieved through use of mechanical force to remove devitalized tissue (e.g. wet-to-dry dressing, pressurized wound irrigation, pulse-lavage); however, this process will remove both healthy and non-healthy tissue and is therefore considered a non-selective debridement method. Enzymatic debridement: A process of debridement in which enzymes such as proteinases or collagenases are applied topically to digest devitalized tissue. Depending on the agent, this process can be either selective or non-selective. Examples include trypsin, streptokinase-streptodornase combination, subtilisin, papain, and collagenase. Surgical debridement: Also known as sharp debridement, this is a process in which devitalized tissue is removed through use of surgical instruments such as scalpels, curettes, or surgical scissors. Surgical debridement can be done in a hospital bed, in an outpatient clinic, or in an operating room depending on the particular wound, risk of bleeding, and anesthesia requirements. Biological debridement: Also known as larval therapy, biological debridement is done through controlled application of sterile larvae (Lucilia sericata) to the wound bed. These larvae release proteolytic enzymes which dissolve necrotic tissue before then ingesting the now debrided tissue.
== History == It came into existence on 1 February 1985 when the Progeny Testing Bull Farm Hisar, which was earlier part of the Government Livestock Farm, Hisar, was transferred from the Government of Haryana state to the Indian Council of Agricultural Research for research on buffaloes (CIRB). On 11 December 1987, a sub-campus near the Bir Dosanjh Wildlife Sanctuary at Nabha in Patiala District was opened, to undertake research on the Nili-Ravi breed of buffalo found in Punjab. In 2016, it became world's second center to produce a cloned buffalo. The first ever successful cloning of buffalo was done by the National Dairy Research Institute, Karnal in 2010
Sources: en.wikipedia.org
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.
Melanotan-1, also called afamelanotide, is a linear analogue with greater selectivity for MC1R and has received approval in some jurisdictions for a specific photosensitivity disorder. Melanotan-2 is cyclic, less selective, and reaches central receptors more readily. The two are often confused in online discussion despite different pharmacology and regulatory status.
Alpha-MSH is an endogenous tridecapeptide derived from pro-opiomelanocortin. Melanotan-2 reproduces its core receptor-binding sequence inside a shortened, stabilised ring. The result is a molecule with a longer effective half-life and higher potency than the parent hormone.
Low temperature slows hydrolysis and oxidation, the two main routes by which the peptide backbone and side chains are modified. A lyophilised powder stored at −20 °C is more stable than one kept at room temperature, and once the material is dissolved the degradation rate rises, making refrigeration more important.